CoChat
Sign Up
Cited by 444SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index, and 1 are not checked yet.

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Open access
Greaney, Allison J., Starr, Tyler N., Barnes, Christopher O., Weisblum, Yiska, Schmidt, Fabian, Caskey, Marina, Gaebler, Christian, Cho, Alice, Agudelo, Marianna, Finkin, Shlomo, Wang, Zijun, Poston, Daniel, Muecksch, Frauke, Hatziioannou, Theodora, Bieniasz, Paul D., Robbiani, Davide F., Nussenzweig, Michel C., Bjorkman, Pamela J., Bloom, Jesse D.·2021·Nature Communications
DOI 10.1038/s41467-021-24435-8PMC PMC7987015

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear. Here we use a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures. We compare the antibody-escape maps to similar maps for convalescent polyclonal plasmas, including plasmas from individuals from whom some of the antibodies were isolated. While the binding of polyclonal plasma antibodies are affected by mutations across multiple RBD epitopes, the plasma-escape maps most resemble those of a single class of antibodies that target an epitope on the RBD that includes site E484. Therefore, although the human immune system can produce antibodies that target diverse RBD epitopes, in practice the polyclonal response to infection is skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24435-8

Cites

76 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Maps of mutations to the RBD that escape binding by three classes of monoclonal antibodies that target the receptor-binding motif. (A) Epitopes for each of the three antibody classes25. ACE2 is shown as a gray cartoon. Some sites fall under both class 1 and class 2 and are shown as an intermediate pink-purple. (B) Escape maps for monoclonal antibodies from each of the three classes. The line plots at left indicate the summed effect of all mutations at each site in the RBD, with larger values indicating a greater reduction in antibody binding. The logo plots at right show the effects of individual mutations at key sites (indicated by purple highlighting on the x-axis of the line plots). In these logo plots, the height of each letter is that mutation’s escape fraction, so larger letters indicate mutations that cause a greater reduction in antibody binding. Sites in the logo plots are colored by RBD epitope. Sites that contact antibody (non-hydrogen atoms within 4Å in high-resolution structures) are highlighted with gray backgrounds. For C110, sites 444, 446, and 447 are unresolved in the structure but are likely in close contact with the antibody, and so are highlighted in gray. The data for LY-CoV016 were previously reported33 and are replotted here. (C) Multidimensional scaling projection of the escape maps, such that antibodies with similar escape mutations are drawn close together. Each antibody is represented as a pie chart colored according to the amount of escape in each RBD epitope. Antibodies for which escape maps are shown in panel (B) have black outlines and colored names. The other antibodies were profiled previously30,33,35,36. Escape maps for all class 1, 2, and 3 antibodies in the plot are shown in Figure S3; for the class 4 antibody-escape maps, see Greaney et al. (2021)30. Colors used in all panels: sites are colored according to epitopes, as defined in Greaney et al. (2021)25. Bright pink for class 1, dark purple for class 2, medium pink-purple for class 1/2 overlap sites (455, 456, 486, 487, 489), cyan for class 3, and gray for all other RBD sites. Escape maps colored according to mutation effects on RBD expression and ACE2 binding are in Figure S4. The ACE2-bound RBD structure in (A) is from PDB 6M0J58.
Figure 1. Maps of mutations to the RBD that escape binding by three classes of monoclonal antibodies that target the receptor-binding motif. (A) Epitopes for each of the three antibody classes25. ACE2 is shown as a gray cartoon. Some sites fall under both class 1 and class 2 and are shown as an intermediate pink-purple. (B) Escape maps for monoclonal antibodies from each of the three classes. The line plots at left indicate the summed effect of all mutations at each site in the RBD, with larger values indicating a greater reduction in antibody binding. The logo plots at right show the effects of individual mutations at key sites (indicated by purple highlighting on the x-axis of the line plots). In these logo plots, the height of each letter is that mutation’s escape fraction, so larger letters indicate mutations that cause a greater reduction in antibody binding. Sites in the logo plots are colored by RBD epitope. Sites that contact antibody (non-hydrogen atoms within 4Å in high-resolution structures) are highlighted with gray backgrounds. For C110, sites 444, 446, and 447 are unresolved in the structure but are likely in close contact with the antibody, and so are highlighted in gray. The data for LY-CoV016 were previously reported33 and are replotted here. (C) Multidimensional scaling projection of the escape maps, such that antibodies with similar escape mutations are drawn close together. Each antibody is represented as a pie chart colored according to the amount of escape in each RBD epitope. Antibodies for which escape maps are shown in panel (B) have black outlines and colored names. The other antibodies were profiled previously30,33,35,36. Escape maps for all class 1, 2, and 3 antibodies in the plot are shown in Figure S3; for the class 4 antibody-escape maps, see Greaney et al. (2021)30. Colors used in all panels: sites are colored according to epitopes, as defined in Greaney et al. (2021)25. Bright pink for class 1, dark purple for class 2, medium pink-purple for class 1/2 overlap sites (455, 456, 486, 487, 489), cyan for class 3, and gray for all other RBD sites. Escape maps colored according to mutation effects on RBD expression and ACE2 binding are in Figure S4. The ACE2-bound RBD structure in (A) is from PDB 6M0J58.CC BY · PubMed Central
Figure 2. Mutations that escape antibody binding are usually in the direct structural footprint. (A) The total escape at each site is mapped onto the surface of the Fab-bound RBD, with white indicating no escape and red indicating the site with the most escape from that antibody. Sites where no mutations are tolerated for RBD folding or ACE2 binding are indicated in dark gray. For C105 and LY-CoV016, gray labels with dashed lines indicate example contact sites with no tolerated mutations. For C110, the general area where site 444 (unresolved in structure) would be located is indicated. (B) Total escape at each site in the RBD, with sites classified according to whether they are an antibody contact (within 4Å), antibody-proximal (4 to 8Å), antibody-distal (>8Å), or unresolved in the Fab-trimer structure. Text indicates the number of sites in each structural category that are sites of “strong escape,” (n / total) shown in orange. See Methods for details and PDB accessions.
Figure 2. Mutations that escape antibody binding are usually in the direct structural footprint. (A) The total escape at each site is mapped onto the surface of the Fab-bound RBD, with white indicating no escape and red indicating the site with the most escape from that antibody. Sites where no mutations are tolerated for RBD folding or ACE2 binding are indicated in dark gray. For C105 and LY-CoV016, gray labels with dashed lines indicate example contact sites with no tolerated mutations. For C110, the general area where site 444 (unresolved in structure) would be located is indicated. (B) Total escape at each site in the RBD, with sites classified according to whether they are an antibody contact (within 4Å), antibody-proximal (4 to 8Å), antibody-distal (>8Å), or unresolved in the Fab-trimer structure. Text indicates the number of sites in each structural category that are sites of “strong escape,” (n / total) shown in orange. See Methods for details and PDB accessions.CC BY · PubMed Central
Figure 3. The mutations that reduce binding of polyclonal plasma often differ from those that reduce binding by monoclonal antibodies isolated from the same individual. (A) Table indicating which plasma and antibodies were derived from the same individual. (B) Escape maps for the polyclonal plasma antibodies, as in Figure 1B. The y-axis is scaled separately for each plasma (see Methods). When there are monoclonal antibodies isolated from the same individual, the total monoclonal antibody escape at each site is shown using the heat maps above the escape maps, with white indicating no effect and black indicating strong escape. (C) Correlation of plasma and monoclonal antibody escape for each plasma / antibody pair from the same individual. Each point in the scatter plots is a site, with the x-axis indicating the total escape at that site for the antibody and the y-axis indicating the total escape at that site for the plasma. Key sites are labeled. Pearson’s R shown above each plot. Colors in B, C reflect antibody classes as in Figure 1.
Figure 3. The mutations that reduce binding of polyclonal plasma often differ from those that reduce binding by monoclonal antibodies isolated from the same individual. (A) Table indicating which plasma and antibodies were derived from the same individual. (B) Escape maps for the polyclonal plasma antibodies, as in Figure 1B. The y-axis is scaled separately for each plasma (see Methods). When there are monoclonal antibodies isolated from the same individual, the total monoclonal antibody escape at each site is shown using the heat maps above the escape maps, with white indicating no effect and black indicating strong escape. (C) Correlation of plasma and monoclonal antibody escape for each plasma / antibody pair from the same individual. Each point in the scatter plots is a site, with the x-axis indicating the total escape at that site for the antibody and the y-axis indicating the total escape at that site for the plasma. Key sites are labeled. Pearson’s R shown above each plot. Colors in B, C reflect antibody classes as in Figure 1.CC BY · PubMed Central
Figure 4. The escape maps of convalescent polyclonal plasma most resemble class 2 antibodies. (A) Multidimensional scaling projection of the escape maps of polyclonal plasma and monoclonal antibodies of each class. Antibodies or plasma that are nearby in the plot have their binding affected by similar RBD mutations. The antibodies are those in Figure 1C, colored according to antibody class. The five plasma newly mapped in this study are shown in green, and the previously mapped 23 plasma18 are shown in white. (B) Structural projection of sites where mutations reduce binding by each class of monoclonal antibodies (left) or polyclonal plasma (right). The RBD surface coloring is scaled from white to red, with white indicating no escape, and red indicating the site with the greatest average site-total escape for all antibodies or plasma in that group. Mutations to sites such as E484, F456, and F486 have some of the largest effects on binding by polyclonal plasma and class 2 antibodies.
Figure 4. The escape maps of convalescent polyclonal plasma most resemble class 2 antibodies. (A) Multidimensional scaling projection of the escape maps of polyclonal plasma and monoclonal antibodies of each class. Antibodies or plasma that are nearby in the plot have their binding affected by similar RBD mutations. The antibodies are those in Figure 1C, colored according to antibody class. The five plasma newly mapped in this study are shown in green, and the previously mapped 23 plasma18 are shown in white. (B) Structural projection of sites where mutations reduce binding by each class of monoclonal antibodies (left) or polyclonal plasma (right). The RBD surface coloring is scaled from white to red, with white indicating no escape, and red indicating the site with the greatest average site-total escape for all antibodies or plasma in that group. Mutations to sites such as E484, F456, and F486 have some of the largest effects on binding by polyclonal plasma and class 2 antibodies.CC BY · PubMed Central
Figure 5. Escape maps predict mutations that are selected during viral growth in the presence of monoclonal antibodies. (A) Mutations selected when chimeric VSV encoding the SARS-CoV-2 spike was grown in the presence of each of the three indicated antibodies by Weisblum et al. (2020)7. Each point represents a different amino-acid mutation, with the x-axis indicating how strongly the mutation escapes antibody binding (measured in the current study) and the y-axis indicating how well the mutant binds to ACE2 (measured in Starr et al. (2020)32). The red diamonds indicate the mutations selected in VSV-spike by Weisblum et al., the gray circles indicate all other amino-acid mutations accessible by a single-nucleotide change, and the brown x’s indicate amino-acid mutations that require multiple nucleotide changes to the codon. (B) Logo plots showing the effects of only single-nucleotide accessible amino-acid mutations on antibody binding. Mutations selected in VSV-spike virus by Weisblum et al. are colored red. (C) The correlation of the effects of mutations on antibody binding measured in the current study and effects on viral neutralization previously measured by Weisblum et al. 7 using chimeric VSV (top) or lentiviral particles (bottom). The x-axis shows the escape fraction measured in the current study, and the y-axis shows the fold-change in IC50 for viral neutralization caused by that mutation, such that larger numbers correspond to greater reductions in neutralization sensitivity. For effects of all antibody- and plasma-binding-escape mutations on ACE2 binding and RBD expression, see Figure S4. For each mutation’s escape fraction compared to fold-change IC50 against each monoclonal antibody or polyclonal plasma tested in Weisblum et al.7, see Figure S6.
Figure 5. Escape maps predict mutations that are selected during viral growth in the presence of monoclonal antibodies. (A) Mutations selected when chimeric VSV encoding the SARS-CoV-2 spike was grown in the presence of each of the three indicated antibodies by Weisblum et al. (2020)7. Each point represents a different amino-acid mutation, with the x-axis indicating how strongly the mutation escapes antibody binding (measured in the current study) and the y-axis indicating how well the mutant binds to ACE2 (measured in Starr et al. (2020)32). The red diamonds indicate the mutations selected in VSV-spike by Weisblum et al., the gray circles indicate all other amino-acid mutations accessible by a single-nucleotide change, and the brown x’s indicate amino-acid mutations that require multiple nucleotide changes to the codon. (B) Logo plots showing the effects of only single-nucleotide accessible amino-acid mutations on antibody binding. Mutations selected in VSV-spike virus by Weisblum et al. are colored red. (C) The correlation of the effects of mutations on antibody binding measured in the current study and effects on viral neutralization previously measured by Weisblum et al. 7 using chimeric VSV (top) or lentiviral particles (bottom). The x-axis shows the escape fraction measured in the current study, and the y-axis shows the fold-change in IC50 for viral neutralization caused by that mutation, such that larger numbers correspond to greater reductions in neutralization sensitivity. For effects of all antibody- and plasma-binding-escape mutations on ACE2 binding and RBD expression, see Figure S4. For each mutation’s escape fraction compared to fold-change IC50 against each monoclonal antibody or polyclonal plasma tested in Weisblum et al.7, see Figure S6.CC BY · PubMed Central
Figure 6. Mutations that escape binding by antibodies and plasma among sequenced SARS-CoV-2 isolates. (A) The total escape at each site averaged across antibodies in each class versus frequency of mutations at each site in GISAID sequences as of March 15, 2021. (B) The total escape at each site averaged across the polyclonal plasma versus frequency of mutations at each site in GISAID sequences. Left: plasma samples profiled in this study, right: plasma samples profiled previously18. (C) Antibody-escape mutations found in emerging viral lineages. RBD mutations in each lineage are assigned to the class of antibody they most strongly escape (e.g., E484K most strongly escapes class 2 antibodies but may also affect some class 1 antibodies). Other RBD mutations present in each viral lineage with negligible effects on binding of these antibodies are listed at right. For numbers of antibodies in each class, see n indicated in each panel in A and B. In each plot, key sites are labeled and colored according to RBD epitope using the same color scheme as in Figure 1.
Figure 6. Mutations that escape binding by antibodies and plasma among sequenced SARS-CoV-2 isolates. (A) The total escape at each site averaged across antibodies in each class versus frequency of mutations at each site in GISAID sequences as of March 15, 2021. (B) The total escape at each site averaged across the polyclonal plasma versus frequency of mutations at each site in GISAID sequences. Left: plasma samples profiled in this study, right: plasma samples profiled previously18. (C) Antibody-escape mutations found in emerging viral lineages. RBD mutations in each lineage are assigned to the class of antibody they most strongly escape (e.g., E484K most strongly escapes class 2 antibodies but may also affect some class 1 antibodies). Other RBD mutations present in each viral lineage with negligible effects on binding of these antibodies are listed at right. For numbers of antibodies in each class, see n indicated in each panel in A and B. In each plot, key sites are labeled and colored according to RBD epitope using the same color scheme as in Figure 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 1

  1. Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. https://doi.org/10.1038/s41591-021-01294-w (2021). · DOI · Paper page

Cited by

Sorted by citations

See all 444

Related

Metadata

Authors
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., Wang, Z., Poston, D., Muecksch, F., Hatziioannou, T., Bieniasz, P. D., Robbiani, D. F., Nussenzweig, M. C., Bjorkman, P. J., & Bloom, J. D.
Affiliations
  • University of Washington (US)
  • Howard Hughes Medical Institute (US)
  • California Institute of Technology (US)
  • Rockefeller University (US)
  • Institute for Research in Biomedicine (CH)
Corresponding author
Bloom, Jesse D.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-07-07
Volume
12
Issue
1
Pages
4196-4196
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-24435-8
PMC
PMC7987015
OpenAlex
W3179259355
Cited by
433
References
64
Citations by year
2026: 34 · 2025: 39 · 2024: 56 · 2023: 83 · 2022: 157 · 2021: 64
FWCI
29.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Howard Hughes Medical Institute
  • Burroughs Wellcome Fund
  • Bill and Melinda Gates Foundation (INV-004949)
  • Damon Runyon Cancer Research Foundation (DRG-2381-19)
  • Washington Research Foundation
  • Fred Hutchinson Cancer Research Center
  • George Mason University
  • California Institute of Technology
  • University of Washington
  • National Institutes of Health (1s10od028685-01, P01-AI138398-S1, AI111825)
  • Beckman Institute, California Institute of Technology
  • National Institute of Allergy and Infectious Diseases (U01AI151698, P01 AI138398-S1, R01AI127893, T32AI083203, U19AI111825, R01AI141707, AI151698, F30AI157898)
  • Office of Research Infrastructure Programs, National Institutes of Health (S10OD028685)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
SARS-CoV-2, spike protein receptor-binding domain, antibody escape mutations, neutralizing antibodies, monoclonal antibodies, convalescent plasma, antibody-antigen binding, epitope evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review